Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2015

View Archived Issues

New assay using HEV-V-LP shows optimal performance in HEV seroprevalence diagnosis

Cell therapy for EBV-positive non-Hodgkin's lymphomas granted orphan status

Epothilone B shows potential for use after CNS injury

University of Nottingham licenses monoclonal antibody platforms from Open Monoclonal Technology

Patiromer controls hyperkalemia in HF patients receiving RAASi

New Fleming Fund aims to tackle drug-resistant infections

Anti-INSR MAb shows potential for the treatment of endogenous hyperinsulinemic hyperglycemia

AbbVie licenses anti-tau antibodies from C2N Diagnostics for Alzheimer's disease therapy

Lupin describes calcium sensing receptor modulators

Lilly and Hanmi to collaborate on development of BTK inhibitor HM-71224

Additional approvals for daclatasvir and asunaprevir in Japan

Trimel's testosterone nasal gel shows efficacy in hypogonadal men

JZoloft approved for post-traumatic stress disorder in Japan

FDA advisory committee recommends approval of BreoEllipta for asthma in adults

PTC Therapeutics and University of Pennsylvania form orphan disease research collaboration

Aurigene patents PD-1 signaling inhibitors

GlaxoSmithKline describe sGC activators

Piramal patents IGF-1 receptor inhibitors

MolMed and GSK enter strategic agreement in gene therapy

Kissei's doxapram approved in Japan for apnea of prematurity

Amgen AstellasBioPharma submits NDA for evolocumab in Japan

Silence Therapeutics reports results from phase Ib/IIa trial of ATU-027 in pancreatic cancer

NIH grants supports work at Scripps Research Institute on autophagy pathway for cancer

Eli Lilly and Innovent Biologics collaborate on cancer drug development in China

New formulation of Verona Pharma's RPL-554 well tolerated in healthy volunteers

ACS Denver: GSK second-generation HCV polymerase inhibitor shows promising results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...